Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00491075 · ClinicalTrials.gov registry record · Phase 2
Pemetrexed Plus Gemcitabine in Renal Cell Cancer
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT00491075: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT00491075 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 16 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00491075, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
Primary Objective: * To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS). Secondary Objectives: * To determine the toxicity of Pemetrexed + Gemcitabine in non-clear cell RCC. * To estimate the survival rate of patients with non-clear cell RCC treated with this combination.
Interventions
- DRUG Pemetrexed
- DRUG Gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2005-12 |
| Est. Completion | 2011-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00491075
The ClinicalTrials.gov registry entry for NCT00491075 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pemetrexed is the first listed.
NCT00491075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00491075 about?
NCT00491075 is a clinical study titled "Pemetrexed Plus Gemcitabine in Renal Cell Cancer". Primary Objective: * To determine the clinical activity of Pemetrexed + Gemcitabine in non-clear cell renal cell cancer (RCC). Clinical activity will take into account response rate and progression free survival (PFS). Secondary Objectives: * To determine the toxicity of Pemetrexed + Gemcitabine ...
What is the current status of trial NCT00491075?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2005-12. Estimated completion is 2011-09.
What interventions are being tested in trial NCT00491075?
The interventions under investigation include: Pemetrexed (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00491075?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.